16:15 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

J&J planning submission for Invokana in CKD following Phase III readout

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) said Invokana canagliflozin met the primary endpoint in the Phase III CREDENCE trial to treat chronic kidney disease in patients with Type II diabetes. A...
22:10 , Jul 16, 2018 |  BC Extra  |  Clinical News

J&J planning submission for Invokana in CKD

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) said Invokana canagliflozin met the primary endpoint in the Phase III CREDENCE trial to treat chronic kidney disease in patients with Type II diabetes. A...
19:50 , Jul 6, 2018 |  BC Extra  |  Preclinical News

New uses for marketed drugs in tough-to-treat indications

Two studies in Science Translational Medicine suggest three generics could be repurposed for difficult to treat indications. A paper from University of Edinburgh researchers showed that endothelial cell-targeted drugs simvastatin and perindopril could help treat patients...
23:29 , Apr 13, 2018 |  BioCentury  |  Tools & Techniques

Personalizing prevention

PlaqueTec Ltd. is working to bring personalized medicine to the cardiovascular space with a device that samples local concentrations of molecules near atherosclerotic plaques. By using these samples to identify prognostic and predictive biomarkers, the...
19:15 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

AZ, Acerta report additional Phase II data for Calquence in MCL

AstraZeneca plc (LSE:AZN; NYSE:AZN) and Acerta Pharma B.V. (Oss, the Netherlands) reported additional data from the Phase II ACE-LY-004 trial in 124 patients with relapsed or refractory mantle cell lymphoma (MCL) showing that Calquence acalabrutinib...
05:39 , Jan 19, 2018 |  BC Week In Review  |  Financial News

Pherecydes raises €8.7M series B

Anti-infectives company Pherecydes Pharma S.A. (Romainville, France) raised €8.7 million ($10.6 million) in a series B round led by new investor GO Capital on Jan. 16. New investors Omnes Capital and Fa Dièse and other...
21:47 , Nov 30, 2017 |  BC Innovations  |  Targets & Mechanisms

All-purpose HSCs

While most eyes are on hematopoietic stem cells for their ability to treat blood cancers, a UCSD group has built a body of work showing the immune cell precursors can treat diseases with no relation...
21:20 , Nov 22, 2017 |  BC Extra  |  Clinical News

Researchers use RWE to reproduce trial results

In an article published in the Journal of the American Medical Association, a team of Harvard researchers used real-world evidence from a U.S. health insurance database to replicate the results of a randomized clinical trial...
04:51 , Nov 3, 2017 |  BC Week In Review  |  Clinical News

FDA approves AZ's Btk inhibitor Calquence for MCL

FDA granted accelerated approval to Calquence acalabrutinib (formerly ACP-196) from AstraZeneca plc (LSE:AZN; NYSE:AZN) and Acerta Pharma B.V. (Oss, the Netherlands) to treat mantle cell lymphoma in adults who have received ≥1 prior therapy. The...
20:46 , Oct 31, 2017 |  BC Extra  |  Company News

FDA approves AZ’s Btk inhibitor for MCL

FDA granted accelerated approval to Calquence acalabrutinib (formerly ACP-196) from AstraZeneca plc (LSE:AZN; NYSE:AZN) and Acerta Pharma B.V. (Oss, the Netherlands) to treat mantle cell lymphoma in adults who have received at least one prior...